Drugs / SCTV01E-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05522829 | Oct → Dec 2022 | COVID-19 | Sinocelltech Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCTV01E-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05522829 ↗ |
| Modality | Vaccine | “Recombinant Protein COVID-19 Vaccine SCTV01E-1” NCT05522829 ↗ |
| Route | Intramuscular | “Day 0; intramuscular injection” NCT05522829 ↗ |